COX-2 Inhibitors at The 8th International Conference of the Inflammation Research Association

Bibliography

• VANE JR, BOTTING RM: New insights into the mode of action of anti-inflammatory drugs. Inflamm. Res. (1995) 44:1–10.
   PubMed Web of Science ®Google Scholar
• GOETZL EJ, AN S, SMITH WL: Specificity of expression and effects of eicosanoid mediators in normal physiol-ogy and human diseases. FASEB J (1995) 9:1051–1058.
   PubMed Web of Science ®Google Scholar
• VANE JR: Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature New Biology (1971) 231:232–235.
   PubMedGoogle Scholar
• KUNKEL SL, CHENSUE SW: Prostaglandins and the regu-lation of immune responses. Adv. Inflamm. Res. (1984) 7:93–109.
   Google Scholar
• ZURIER RB: Role of prostaglandin E in inflammation and immune responses. Adv. Prostaglandin, Thromboxane and Leukotriene Res. (1990) 21:947–953.
   Google Scholar
• KLOEZE J: Influence of prostaglandins on platelet adhe-siveness and platelet aggregation. In: Prostaglandins, Proceedings of the Second Nobel Symposium. Bergstrom S, Samuelsson B (Eds.), (1966):241–252.
   Google Scholar
• GOODWIN JS, CEUPPENS J: Regulation of the immune response by prostaglandins. J. Clin. Immunol. (1983)4:295-315. Good review of early work in this area.
   Google Scholar
• WEBB DR, OSHEROFF PL: Antigen stimulation of pro-staglandin synthesis and control of immune responses. Proc. Natl. Acad. Sci. (1976) 73:1300–1304.
   PubMed Web of Science ®Google Scholar
• YOUNG MR, DIZER M: Enhancement of immune func-tion and tumor growth inhibition by antibodies against prostaglandin E2. Immunolog Commun. (1983) 12:11–23.
   PubMed Web of Science ®Google Scholar
• MARKEWITZ A, FAIST E, LANG S et al: Successful resto-ration of cell-mediated immune response after cardio-pulmonary bypass by immunomodulation. j Thorac. Cardiovasc. Surg (1993) 105:15–24.
   PubMed Web of Science ®Google Scholar
• FAIST E, ERTEL W, COHNERT T et al.: Immunoprotective effects of cyclo-oxygenase inhibition in patients with major surgical trauuma. J. Trauma (1990) 30:8–18.
   PubMed Web of Science ®Google Scholar
• ASPINALL RL, CAMMARATA PS: Effect of prostaglandin Ey on adjuvant arthritis. Nature (1969) 224:1320–1321.
   PubMed Web of Science ®Google Scholar
• ZURIER RB, QUAGLIATA F: Effect of prostaglandin Et on adjuvant arthritis. Nature (1971) 234:304-305. These authors presented some of the earliest, most convincing data on the immunosuppressive effects of prostaglandins in animals.
   Google Scholar
• BONTA IL, PARNHAM MJ, VAN VLIET L: Combination of theophylline and prostaglandin Et as inhibitors of the adjuvant-induced arthritis syndrome of rats. Ann. Rheum. Dis. (1978) 37:212–217.
   PubMed Web of Science ®Google Scholar
• KUNKEL SL, THRALL RS, KUNKEL RG et al.: Suppression of immune complex vasculitis in rats by prostaglandin. Clin. Invest. (1979) 64:1525–1529.
   Google Scholar
• HEDQVIST P, RAUD J, DAHLEN SE: Dual action of pro-staglandin E2 in allergic inflammation. Adv. Prostaglandin, Thromboxane and Leukotriene Res. (1989) 19:539–542.
   PubMedGoogle Scholar
• FANTONE JC, KUNKEL SL, WARD PA, ZURIER RB: Suppres-sion by prostaglandin Ei of vascular permeability in-duced by vasoactive inflammatory mediators. J. Immunol. (1980) 125:2591–2596.
   PubMed Web of Science ®Google Scholar
• BONTA IL, PARNHAM MJ: Time-dependent stimulatory •and inhibitory effects of pr ostaglandin Et on exudative and tissue components of granulomatous inflamma-tion in rats. Br. J Pharmacol. (1979) 65:465-472. The authors present a good discussion of possible mechanisms for the pro- and anti-inflammatory effects of prostaglandins.
   Google Scholar
• BONTA IL, ADOLFS MJP, PARNHAM MJ: Prostaglandin E2 elevation of cyclic-AMP in granuloma macrophages at various stages of inflammation: relevance to anti-in-flammatory and immunomodulatory functions. Pro-staglandins (1981) 22:95–103.
   Google Scholar
• RAUD J, DAHLEN SE, SYDBOM A et al: Prostaglandin modulation of mast cell-dependent inflammation. Agents Actions (1989) 26:42–44.
   PubMedGoogle Scholar
• RHEINS LA, BARNES L, AMORNSIRIPANITCH S et al.: Sup-pression of the cutaneous immune response following topical application of the prostaglandin PGE2. Immunol. (1987) 106:33–42.
   Web of Science ®Google Scholar
• ANDERSON CB, GRAFF RJ, JAFFE BM: Prostaglandin E prolongation of murine skin allografts. Surg. Forum (1976): 330–332.
   PubMedGoogle Scholar
• STROM TB, CARPENTER CB, CRAGOE EJ et al.: Suppres-sion of in vivo and in vitro alloimmunity by pro-staglandins. Transplantation Proc. (1977) IX:1075–1079.
   Google Scholar
• STROM TB, CARPENTER CB: Prostaglandin as an effective antirejection therapy in rat renal allograft recipients. Transplantation (1983) 35:279–281.
   PubMed Web of Science ®Google Scholar
• STONE CD, ROSENGARD BR, BOORSTEIN SM et al.: Pro-staglandin Ey inhibits in vitro and in vivo lymphocyte responses in allogeneic transplantation. Ann. Thorac. Surg. (1990) 49:927–931.
   PubMed Web of Science ®Google Scholar
• GOODWIN JS, MESSNER RP, PEAKE GT: Prostaglandin suppression of mitogen-stimulated lymphocytes in vi-tro. J. Clin. Invest. (1978) 62:753–760.
   PubMed Web of Science ®Google Scholar
• GOODWIN JS, WIIK A, LEWIS M et al: High-affinity binding sites for prostaglandin E on human lympho-cytes. Cell. Immunol. (1979) 43:150–159.
   PubMed Web of Science ®Google Scholar
• RAPPAPORT RS, DODGE GR: Prostaglandin E inhibits the •production of human interleukin 2. J. Exp. Med. (1982) 155:943-948. This paper links the immunoregulatory effects of prostaglandins with IL-2 inhibition in human peripheral blood lymphocytes.
   Google Scholar
• WALKER C, KRISTENSEN R, BETTENS F, DEWECK AL: Lymphokine regulation of activated (GI) lymphocytes. Immunol (1983) 140:1770–1773.
   Google Scholar
• SMITH JW, STEINER AL, PARKER CW: Human lymphocyte •metabolism. Effects of cyclic and noncyclic nucleotides on stimulation by phytohemagglutinin. J. Clin Invest. (1971) 50:442-448. Early discussion on the effects of cyclic AMP on lymphocyte function.
   Google Scholar
• RINCON M, TUGORES A, LOPEZ-RIVAS A et al: Prostaglandin Ey and the increase of intracellular cAMP inhibit the expression of interleukin-2 receptors in human T-cells. Eur. j ImmunoL (1988) 18:1791–1796.
   PubMed Web of Science ®Google Scholar
• MARY D, AUSSEL C, FERRUA B, FEHLMANN M: Regulation of interleukin-2 synthesis by cAMP in human T-cells. J. Immunol. (1987) 139:1179–1184.
   PubMed Web of Science ®Google Scholar
• KRAUSE DS, DEUTSCH C: Cyclic AMP directly inhibits 11-2 receptor expression in human T-cells: expression of both p55 and p75 subunits is affected. J. Immunol. (1991) 146:2285–2294.
   PubMed Web of Science ®Google Scholar
• BARTIK MM, BROOKS WH, ROSZMAN TL: Modulation of T-cell proliferation by stimulation of the P-adrenergic receptor: lack of correlation between inhibition of T-cell p rolife rat ion and cAMP accumulation. Cell. Immu-nol (1993) 148:408–421.
   PubMed Web of Science ®Google Scholar
• BAUMAN GP, BARTIK MM, BROOKS WH, ROSZMAN TL: Induction of cAMP-dependent protein kinase (PKA) activity in T-cells after stimulation of the prostaglandin E2 or the P-adrenergic receptors: relationship between PKA activity and inhibition of anti-CD3 monoclonal antibody-induced T-cell proliferation. Cell. Immunol. (1994) 158:182–194.
   PubMed Web of Science ®Google Scholar
• WACHOLTZ MC, MINAKUCHI R, LIPSKY PE: Charac-terization o f the 3 ',5'-cyclic adenosine m onophosp hate - mediated regulation of 112 production by T-cells and Jurkat cells. Cell. Immunol. (1991) 135:285–298
   PubMed Web of Science ®Google Scholar
• MINAKUCHI R, WACHOLTZ MC, DAVIS LS, LIPSKY PE:Delineation of the mechanism of inhibition of human T-cell activation by PGE2. J. Immunol (1990) 145:2616–2625.
   PubMed Web of Science ®Google Scholar
• SKALHEGG BS, TASKEN K, HANSSON V et al.: Location of cAMP-dependent protein kinase type I with the TCR-CD3 complex. Science (1994) 263:84–87.
   PubMed Web of Science ®Google Scholar
• WATANABE S, YSSEL H, HARADA Y, ARAI K: Effects of prostaglandin E2 on Th0-type human T-cell clones: modulation of functions of nuclear proteins involved in cytokine production. Int Immunol. (1994) 6:523–532.
   PubMed Web of Science ®Google Scholar
• LINGK DS, CHAN MA, GELFAND EW: Increased cyclic adenosine monophosphate levels block progression but not initiation of human T-cell proliferation. J. hn-munol (1990) 145:449–455.
   PubMed Web of Science ®Google Scholar
• ANASTASSIOU ED, PALIOGIANNI F, BALOW JP et al: Prostaglandin E2 and other cyclic AMP-elevating agents modulate IL-2 and IL-2Ra gene expression at multiple levels. J Immunol. (1992) 148:2845–2852.
   PubMed Web of Science ®Google Scholar
• ABBAS AK, LICHTMAN AH, POBER JS: Types of specific immunity. In: Cellular and Molecular Immunology (2nd Edition). WB Saunders Company (19905.
   Google Scholar
• MOSMANN TR, COFFMAN RL: Thl and Th2 cells: different patterns of lymphokine secretion lead to different functional properties. Ann. Rev. Immunol (1989) 7:145–173.
   PubMed Web of Science ®Google Scholar
• STREET NE, MOSMANN TR: Functional diversity o f T-lym-phocytes due to secretion of different cytokine pat-terns. FASEB J (1991) 5:171–177.
   PubMed Web of Science ®Google Scholar
• ROMAGNANI S: Lymphokine production by human T- •cells in disease states. Ann. Rev. Immunol (1994) 12:227-257. A good review of the functional classification of T-lymphocytes.
   Google Scholar
• GARRA A, MURPHY K: T-cell subsets in autoimmu-nity. Curr. Opin. Immunol. (1993) 5:880–886
   PubMed Web of Science ®Google Scholar
• BETZ M, FOX BS: Prostaglandin E2 inhibits production of Thl lymphokines but not of Th2 lymphokines. J.Immunol. (1991) 146:108-113. This paper demonstrated differential effects of prostaglandins on T-lymphocyte subsets.
   Google Scholar
• SNIJDEWINT FGM, KALINSKI P, WIERENGA EA et al.: Pro-staglandin E2 differentially modulates cytokine secre-tion profiles of human T-helper lymphocytes. J. Immunol (1993) 150:5321–5329.
   PubMed Web of Science ®Google Scholar
• GOLD KN, VVEYAND CM, GORONZY JJ: Modulation ofhelper T-cell function by prostaglandins. Arthritis & Rheumatism (1994) 37:925–933.
   PubMed Web of Science ®Google Scholar
• NOVAK TJ, ROTHENBERG EV: cAMP inhibits induction of interleukin-2 but not of interleukin-4 in T-cells. Proc. Natl. Acad. Sci. USA (1990) 87:9353–9357.
   PubMed Web of Science ®Google Scholar
• LACOUR M, ARRIGHI JF, MULLER KM et al: cAMP up-regu-lates 11-4 and IL-5 production from activated CD4+ T-cells while decreasing IL-2 release and NF-AT induc-tion. International Immunol. (1994) 6:1333–1343.
   PubMed Web of Science ®Google Scholar
• KATAMURA K, SHINTAKU N, YAMAUCHI Y et al.: Pro-staglandin E2 at priming of naive CD4+ T-cells inhibits acquisition of ability to produce IFN-y and 11-2, but not 11-4 and IL-5. J. Immunol. (1995) 155:4604–4612.
   PubMed Web of Science ®Google Scholar
• HILKENS CMU, VERMEULEN H, JOOST VAN NEERVEN RJ et al.: Differential modulation of T-helper type 1 (Thl) and T-helper type 2 (Th2) cytokine secretion by pro-staglandin E2 critically depends on interleukin-2. Eur. Immunol. (1995) 25:59–63.
   Google Scholar
• PARKER CW, HUBER MG, GODT SM: Modulation of IL-4 production in murine spleen cells by prostaglandins. Immunol (1995) 160:278–285.
   Web of Science ®Google Scholar
• PHIPPS RP, STEIN SH, ROPER RL: A new view of pro- staglandin E regulation of the immune response. Immu-nol. Today (1991) 12:349-352. The authors present an excellent discussion of the immunomodula-tory role of prostaglandins in vivo.
   Google Scholar
• VAN DER POUVV KRAAN T, BOEIJE L, SMEENK R et al: Prostaglandin E2 is a potent inhibitor of human inter-leukin-12 production. J. Exp. Med. (1995) 181:775–779.
   PubMed Web of Science ®Google Scholar
• SCOTT P: IL-12: initiation cytokine for cell-mediated immunity. Science (1993) 260:496–497.
   PubMed Web of Science ®Google Scholar
• HILKENS CMU, SNIJDERS A, VERMEULEN H et al.: Acces-sory cell-derived 11-12 and prostaglandin E2 determine the IFN-y level of activated human CD4+ T-cells. Immunol. (1996) 156:1722–1727.
   Web of Science ®Google Scholar
• NUSSENBLATT RB: Experimental autoimmune uveitis: mechanisms of disease and clinical therapeutic indica-tions. Invest Ophthalmol. Visual Sci. (1991) 32:3131–3141.
   PubMed Web of Science ®Google Scholar
• MOCHIZUKI M, NUSSENBLATT RB, KUVVABARA T, GERY I: Effects of cyclosporine and other immunosuppres-sive drugs on experimental autoimmune uveoretinitis in rats. Invest. Ophthalmol Vis Sci. (1985) 26:226–232.
   PubMed Web of Science ®Google Scholar
• SAOUDE A, KUHN J, HUYGEN K et al.: Th2 activated cells prevent experimental autoimmune uveoretinitis, a Thl-dependent autoimmune disease. ELI!: j Immunol. (1993) 23:3096–3103.
   Web of Science ®Google Scholar
• LIBLAU RS, SINGER SM, MCDEVITT HO: Thl and Th2 CD4+ T-cells in the pathogenesis of organ-specific autoim-mune diseases. Immunol. Today (1995) 16:34–38.
   PubMedGoogle Scholar
• RATCLIFFE LT, LUKEY PT, MEYERS OL, RESS SR: Pro-stanoid modulation of synovial antigen-specific CD4+ T-cell cytotoxic function in rheumatoid arthritis. Br. J. Rheumatol (1995) 34:113–120.
   PubMedGoogle Scholar
• HENRIKSSON K, TAGESSON C, URIBE A et al: Effects of prostaglandin E2 on disease activity, gastric secretion and intestinal permeability and morphology in patients with rheumatoid arthritis. Ann. Rheumatic Dis. (1988) 47:620–627.
   PubMed Web of Science ®Google Scholar
• SCHULZE-KOOPS H, LIPSKY PE, KAVANAUGH AF, DAVIS LS: Elevated Thl- or Th0-like cytokine mRNA in periph-eral circulation of patients with rheumatoid arthritis. J. Immunol. (1995) 155:5029–5037.
   PubMed Web of Science ®Google Scholar
• COLLINS PW, DJURIC SW: Synthesis of therapeutically useful prostaglandin and prostacyclin analogs. Chem.Rev. (1993) 93:1533-1564. Excellent overview of the medicinal chemistry efforts surrounding therapeutically useful prostaglandins.
   Google Scholar
• KUNKEL SL, OGAWA H, CONRAN PB et al: Suppression of acute and chronic inflammation by orally adminis-tered prostaglandins. Arthritis Rheumatism (19 8 1 ) 24:1151-1158.
   Google Scholar
• ULICH TR, NI R-X: Inhibition of experimental autoim-mune tubulointerstitial nephritis in Brown-Norway rats by (15S)-15-methyl prostaglandin Et. Autoimmune Tubulointerstitial Nephritis (1986) 124:286–293.
   Google Scholar
• TATE GA, MANDELL BF, SCHUMACHER RH, Jr., ZURIER RB: Suppression of acute inflammation by 15-methyl pro-staglandin Et. Lab. Invest. (1988) 59:192–199.
   PubMed Web of Science ®Google Scholar
• ANDERSON CB, JAFFEE BM, GRAFF RJ: Prolongation of murine skin allografts by prostaglandin Et. Transplan-tation (1977) 23:444–447.
   PubMed Web of Science ®Google Scholar
• ALLGAYER H, DESCHRYVER K, STENSON WF: Treatmentwith 16,16-dimethyl prostaglandin E2 before and after induction of colitis with trinitrobenzenesulfonic acid in rats decreases inflammation. Gastroenterology (1989) 96:1290–1300.
   PubMed Web of Science ®Google Scholar
• SCHREINER GF, KAMEI T, LEFKO WITH J, WAYNE FLYE M: Modulation of the kinetics of the initial leukocyte mi-gration into renal allografts by 16,16-dimethyl PGE2. Transplantation (1993) 56:417–422.
   PubMed Web of Science ®Google Scholar
• POLLAK R, DUMBLE LJ, WIEDERKEHR JC: The immuno-suppressive properties of new oral prostaglandin Et analogs. Transplantation (1990) 50:834–838.
   PubMed Web of Science ®Google Scholar
• HAYNES DR, WHITEHOUSE MW, VERNON-ROBERTS B: The prostaglandin Et analogue, misoprostol, regulates inflammatory cytokines and immune functions in vitro like the natural prostaglandins El, E2 and E3. Immunol-ogy (1992) 76:251–257.
   PubMed Web of Science ®Google Scholar
• WIEDERKEHR JC, DUMBLE L, POLLAK R, MORGAN M: Immuriosuppressive effect of misoprostol: a new syn-thetic prostaglandin Ei analogue. Aust. NZ J. Surg. (1990) 60:121–124.
   PubMedGoogle Scholar
• ALAM R, DEJARNATT A, STAFFORD S et al: Selective inhibition of the cutaneous late but not immediate allergic response to antigens by misoprostol, a PGE analog. Am. Rev. Respk. Dis. (1993) 148:1066–1070.
   PubMed Web of Science ®Google Scholar
• JUAREZ C, ORTIZ J, MOZES M: Effect of a PGE1 analogue on the survival of cardiac transplant rats. Arch. Med. Res. (1992) 23:55–58.
   Google Scholar
• KORT WJ, BONTA IL, ADOLFS MJP, WESTBROEK DL: Synergism of (155)-15-methyl-prostaglandin Ei with either azathioprine or prednisolone on the survival of heart allografts in rats. Prostaglandins Leukotrienes and Medicine (1982) 8:661–664.
   PubMedGoogle Scholar
• OZAWA T, KAMADA N, ASHIZAWA T, AOKI T: Effects of combined therapy with prostaglandin Et and cy-closporine A on rat heart allograft survival. Transplan-tation Proc. (1991) 23:2213–2214.
   PubMed Web of Science ®Google Scholar
• FABREGA AJ, BLANCHARD J, RIVAS PA et al: Prolongation of rat heart allograft survival using cyclosporine and enisoprost, a prostaglandin Ei analog. Transplantation (1992) 53:1363–1367.
   PubMed Web of Science ®Google Scholar
• WANDERS A, TUFVESON G, GERDIN B: Effects of pro-staglandin E2 (PGE2) and drugs affecting PGE2 degrada-tion on acute rejection of rat cardiac allografts. Scand. Thorac. Cardiovasc. Surg. (1992) 26:33–37.
   PubMed Web of Science ®Google Scholar
• KOH I, KIM P, CHUNG SW et al.: The effects of 16, 16 dimethyl prostaglandin E2 therapy alone and in com-bination with low-dose cyclosporine on rat small intes-tinal transplantation. Transplantation (1992) 54:592–598.
   PubMed Web of Science ®Google Scholar
• OLSEN TW, GOTHARD TW, HOLLAN EJ: Misoprostol with cyclosporin A prolongs corneal allograft survival in an animal model. Cornea (1996) 15:76–81.
   PubMed Web of Science ®Google Scholar
• MORAN M, MOZES MF, MADDUX MS et al: Prevention of •acute graft rejection by the prostaglandin Et analogue misoprostol in renal-transplant recipients treated with cyclosporine and prednisone. New Engl. J. Med. (1990) 322:1183-1188. Demonstration of the potential clinical utility of prostaglandins in transplant recipients.
   Google Scholar
• TAKAYA S, MAKI Y, STARZL TE: Liver transplantation in positive cytotoxic crossmatch cases using FK506, high-dose steroids, and prostaglandin Ei. Transplantation (1992) 54: 927–929.
   PubMed Web of Science ®Google Scholar
• ADAMS MB: Enisoprost in renal transplantation. Trans-plantation (1992) 53:338–345.
   Google Scholar
• EIERMAN DF, YAGAMI M, ERME SM: Endogenously op- •sonized particles divert prostanoid action from lethal to protective models of experimental endotoxemia. Proc. Natl. Acad. Sci. (1995) 92:2815-2819. This paper demonstrates that a key element in exploring pro-staglandins as therapeutic agents is the localisation of their activity in vivo.
   Google Scholar
• KENNEDY I, COLEMAN RA, HUMPHREY PPA et al: Studies on the characterization of prostanoid receptors: a pro-posed classification. Prostaglandins (1982) 24:667–689.
   PubMedGoogle Scholar
• COLEMAN RA, SMITH WL, NARUMIYA 5: VIII. Interna-tional Union of lharmacology classification of pro-stanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharma-col. Rev. (1994) 46:205-229. Recent review of prostanoid receptor classification.
   Google Scholar
• WISE H, JONES RL: Characterization of prostanoidr ecep-tors on rat neutrophils. Br. J. Pharmacol (1994) 113:581–587.
   PubMedGoogle Scholar
• WHEELDON A, VARDEY CJ: Characterization of the in-hibitory prostanoid receptors on human neutrophils. Br.j Pharmacol (1993) 108:1051–1054.
   PubMed Web of Science ®Google Scholar
• TALPAIN E, ARMSTRONG RA, COLEMAN RA VARDEY CJ: Characterization of the P GE receptor subtype mediating inhibition of superoxide production in human neutro-phils. Br. J. Pharmacol (1995) 114:1459–1465.
   PubMed Web of Science ®Google Scholar
• ARMSTRONG RA: Investigation of the inhibitory effects of PGE2 and selective EP agonists on chemotaxis of human neutrophils. Br. J. Pharmacol (1995) 116:2903–2908.
   PubMed Web of Science ®Google Scholar
• DE VRIES GW, GUARINO P, MCLAUGHLIN A eta].: An EP receptor with a novel pharmacological profile in the T-cell line Jurkat Br. J. Pharmacol (1995) 115:1231–1234.
   Google Scholar
• COLEMAN RA, GRIX SP, HEAD SA et al: A novel inhibitory prostanoid receptor in piglet saphenous vein. Pro-staglandins (1994) 47:151–168.
   PubMed Web of Science ®Google Scholar
• MORI K, TANAKA I, KOTANI M eta].: Gene expression of the human prostaglandin E receptor EP4 subtype: dif-ferential regulation in monocytoid and lymphoid line-age cells by phorbol ester. J. Mol. Med. (1996) 74:333–336.
   Google Scholar
• BLASCHKE V, JUNGERMANN K, PUSCHEL GP: Exclusive expression of the Gs-lirked prostaglandin Ey receptor subtype 4 mRNA in human mononuclear Jurkat and KM-3 cells and coexpression of subtype 4 and 2 mRNA in U-937 cells. FEBS Lett. (1996) 394:39–43.
   PubMed Web of Science ®Google Scholar
• ZENG L, AN S, GOETZL EJ: Selective regulation of RNK-16cell matrix metalloproteinases by the EP4 subtype of prostaglandin Ey receptor. Biochemistry (1996) 35:7159–7164.
   PubMed Web of Science ®Google Scholar